Shots: 

• Collaboration is focused on using Regeneron’s Velocisuite platform for the discovery and characterization of human antibodies- T cell receptors and bluebird will contribute in gene transfer and cell therapy
• The program has six initial targets with additional targets may be selected in five year term 50/50 R&D cost sharing till IND application. Regeneron has option to opt-in co-development/co-commercialization for certain undisclosed targets- with 50/50 cost and profit sharing. Regeneron to receive milestone payments and royalties in case of non-exercise of option on any potential resulting products 
• Regeneron will also make a $100M investment in bluebird’s common stock at a price of $238.10/ share- at a premium of 59% on Aug 3- 2018. The premium includes ~$37M credited against Regeneron’s initial 50 % funding R&D collaboration 

/ article | Ref: Bluebird bio | Image: EHSCareers